HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosmetic Safety Enhancement Act Advances In US House, Still Without Preemption

Executive Summary

Approved by the House Energy and Commerce Health Subcommittee on 11 March, H.R. 5279 still lacks any concrete provisions regarding federal preemption of state and local requirements, though bill author and full committee chair Frank Pallone, D-NJ, remains committed to discussions on the subject. He recognized preemption as “a major issue that I know we have to deal with.”

You may also be interested in...



MoCRA: No User Fees, Not Overly Prescriptive, And Could Help Tamp Down State Legislation

Independent Beauty Association CEO and president Don Frey and cosmetics industry lobbyist Robert Harmala of Telegraph Avenue Advisor, provided views on the Modernization of Cosmetic Regulations Act and developments to come at IBA’s Cosmetic Technical/Regulatory Forum.

PCPC Senior Leaders Discuss Historic 2022 And What’s To Come In New Cosmetics Regulatory Era

HBW Insight spoke with the Personal Care Products Council’s Karin Ross, executive VP of government affairs, and Tom Myers, executive vice president for legal and regulatory affairs and general counsel, to discuss the Modernization of Cosmetic Regulations Act and PCPC’s role to support members’ compliance going forward.

Senate HELP Floats Draft For US Cosmetics Reform; Top Trade Groups Hustle To Respond

Bundled within the draft FDA Safety and Landmark Enhancements Act are federal cosmetics reform provisions that would require facility registration and product listings with the US FDA, adverse event reporting and good manufacturing practices, while empowering the agency to order product recalls, access company records, and suspend dangerous operations.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149785

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel